Ruidi Biotechnology

Explore the latest insights on Ruidi Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Ruidi Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Ruidi Biotechnology and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Ruidi Biotechnology's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

TYK Medicines' Asandeutertinib (TY‑9591) Set to Ship First Commercial Batch – Qilu Pharmaceutical to Launch China Sales of the NMPA‑Approved EGFR‑TKI
CompanyDrug

TYK Medicines’ Asandeutertinib (TY‑9591) Set to Ship First Commercial Batch – Qilu Pharmaceutical to Launch China Sales of the NMPA‑Approved EGFR‑TKI

TYK Medicines (HKG: 2410) announced that its independently developed new drug, asandeutertinib (TY‑9591), is set to complete production, with the first batch expected to be officially shipped via commercial channels…

Abbisko's PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor

Abbisko’s PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
NMPA Approves Hangzhou Ruidi Biotechnology's Steep Pulse Therapy Equipment for Tumor Treatment
CompanyMedical Device

NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment